- Home
- NKGN vs KZIA Comparison
NKGN vs KZIA Comparison
Compare NKGN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKGN
- KZIA
- Stock Information
- Founded
- NKGN 2017
- KZIA 1994
- Country
- NKGN United States
- KZIA Australia
- Employees
- NKGN N/A
- KZIA N/A
- Industry
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- NKGN Health Care
- KZIA Health Care
- Exchange
- NKGN Nasdaq
- KZIA Nasdaq
- Market Cap
- NKGN 14.1M
- KZIA 12.6M
- IPO Year
- NKGN N/A
- KZIA 1999
- Fundamental
- Price
- NKGN $0.37
- KZIA $0.42
- Analyst Decision
- NKGN
- KZIA Strong Buy
- Analyst Count
- NKGN 0
- KZIA 1
- Target Price
- NKGN N/A
- KZIA $2.00
- AVG Volume (30 Days)
- NKGN 447.1K
- KZIA 1.7M
- Earning Date
- NKGN 11-12-2024
- KZIA 10-15-2024
- Dividend Yield
- NKGN N/A
- KZIA N/A
- EPS Growth
- NKGN N/A
- KZIA N/A
- EPS
- NKGN N/A
- KZIA N/A
- Revenue
- NKGN N/A
- KZIA $382.00
- Revenue This Year
- NKGN N/A
- KZIA $4,053,954.00
- Revenue Next Year
- NKGN N/A
- KZIA N/A
- P/E Ratio
- NKGN N/A
- KZIA N/A
- Revenue Growth
- NKGN N/A
- KZIA N/A
- 52 Week Low
- NKGN $0.35
- KZIA $0.19
- 52 Week High
- NKGN $5.10
- KZIA $1.58
- Technical
- Relative Strength Index (RSI)
- NKGN 28.92
- KZIA 56.50
- Support Level
- NKGN $0.36
- KZIA $0.38
- Resistance Level
- NKGN $0.44
- KZIA $0.46
- Average True Range (ATR)
- NKGN 0.04
- KZIA 0.04
- MACD
- NKGN 0.01
- KZIA 0.01
- Stochastic Oscillator
- NKGN 10.58
- KZIA 52.70
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.